<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet type="text/xsl" href="/wp-content/plugins/xml-sitemap-feed/assets/sitemap-news.xsl?ver=5.7.7"?>
<!-- generated-on="2026-11-12T01:39:31+00:00" -->
<!-- generator="XML Sitemap & Google News for WordPress" -->
<!-- generator-url="https://status301.net/wordpress-plugins/xml-sitemap-feed/" -->
<!-- generator-version="5.7.7" -->
<urlset xmlns="http://www.sitemaps.org/schemas/sitemap/0.9" xmlns:news="http://www.google.com/schemas/sitemap-news/0.9" >
<url><loc>https://www.medicinanews.it/foundayo-glp-1-orale-eli-lilly/369259/</loc><news:news><news:publication><news:name>Medicinanews.it</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-11-10T15:24:10+01:00</news:publication_date><news:title>Tirzepatide orale: il nuovo farmaco GLP-1 di Eli Lilly per diabete e controllo del peso</news:title></news:news></url>
<url><loc>https://www.medicinanews.it/farmaci-glp1-rischi-oculari-evidenze/369256/</loc><news:news><news:publication><news:name>Medicinanews.it</news:name><news:language>it</news:language></news:publication><news:publication_date>2026-11-10T12:20:59+01:00</news:publication_date><news:title>Farmaci GLP-1: i rischi oculari emergenti e le sfide dell&#8217;aderenza terapeutica nel diabete</news:title></news:news></url>
</urlset>
